Regeneron opens the week with analyst focus, shares on NASDAQ radar

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-30, 12:33.

Regeneron (US75886F1075) starts the week with attention on its position among large-cap US biotech names. The stock is listed on NASDAQ, putting it into direct comparison with sector peers such as Amgen and Gilead Sciences.

What the Street watches today

Analyst coverage on Regeneron typically focuses on three pillars: earnings visibility from marketed drugs, the depth of the research pipeline, and capital allocation discipline. Large US and European houses regularly publish updates with rating changes and adjusted price targets.

In practice, that means investors look at how many analysts rate the stock Buy versus Hold or Sell, and how the average 12-month price target compares with the current NASDAQ quotation. Rating distribution and target dispersion are standard tools for assessing the perceived risk-reward profile.

Consensus and biotech context

Beyond headline ratings, consensus models project revenue and earnings trajectories over several years. For a biotech group like Regeneron, the shape of the growth curve across immunology, ophthalmology and oncology franchises is a central input for those models.

Comparison with peers such as Amgen and Gilead Sciences helps investors understand whether Regeneron is expected to grow faster, slower or in line with the broader large-cap biotech cohort. That relative view often influences how portfolio managers size positions in the stock.

How Regeneron makes its money

Regeneron generates revenue mainly from biologic medicines in areas such as inflammatory diseases and eye conditions, supported by collaborations with other pharmaceutical companies. A representative product for the group is Dupixent, a monoclonal antibody used to treat certain allergic and inflammatory conditions.

Where the shares trade today

Regeneron shares (US75886F1075) trade on NASDAQ in US dollars. As of 2026-06-30, 12:33, the latest price data are not independently verified here, but the listing remains a reference point for biotech-focused investors following US equities.

Disclaimer: This text is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell securities, or a solicitation of any transaction. All data are based on publicly available information believed to be reliable but not independently verified in real time.